cariboubio.com - CRBU Enterprise Value-to-Sales Ratio

Public company logo of Caribou Biosciences Inc. (CRBU)

Caribou Biosciences (CRBU) develops advanced gene-editing systems, utilizing chRDNA for ultra-precise CAR-T therapies. The firm's EV/Sales multiple valuation reflects market dynamics, with the value stabilizing at -3699.15. While demand for medicine remains stable, sanctions and patent disputes complicate global trials. The success of CRISPR projects is critical, but a sufficient liquidity cushion minimizes current financial risks.

cariboubio.com (CRBU): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 11/20/2026

Financial and market metric breakdowns for Caribou Bio (CRBU)

- money and cash flow information:
Fundamental valuation:Caribou Biosciences (CRBU)
Core merchandise of Caribou Biosciences Inc.

The selection of defensive assets is based on identifying undervalued growth potential. In Caribou Biosciences (CRBU), this resource is driven by Rachel Haurwitz's scientific expertise in precision genome editing. The EV/Sales multiple compares the total enterprise value with revenue, excluding the impact of debt load. The EV/Sales trend signals whether shares are overbought or undervalued. Exceeding market norms indicates inflated expectations for the company's future breakthroughs.